Cohance Lifesciences Ltd. Financials: Quarterly Results
Revenue
550.71
Cr.
PAT
29.02
Cr.
EBITDA
54.57
Cr.
Cohance Lifesciences Ltd. Q1FY26 Financial Metrics
| Indicator | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 544.55 | 555.57 | 549.31 | 402.02 | 307.15 |
| Total Income From Operations (Cr.) | 544.55 | 555.57 | 549.31 | 402.02 | 307.15 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 54.57 | 92.53 | 81.04 | 57.35 | 113.06 |
| P/L Before Exceptional Items & Tax (Cr.) | 45.46 | 83.77 | 70.86 | 51.60 | 109.73 |
| P/L After Tax from Ordinary Activities (Cr.) | 29.02 | 66.39 | 46.40 | 38.73 | 83.29 |
| Net Profit/Loss For the Period (Cr.) | 29.02 | 66.39 | 46.40 | 38.73 | 83.29 |
| Basic EPS | 0.96 | 1.94 | 1.28 | 1.65 | 3.26 |
FAQs
Cohance Lifesciences Ltd. announced its quarterly results for Q1 FY2026 on August 13, 2025.
In Q1 FY2026, Cohance Lifesciences Ltd. are as follows:
Revenue: ₹550.71 crore
Net Profit: ₹29.02 crore.
For Q1 FY2026, Cohance Lifesciences Ltd. posted ₹550.71 crore in revenue and ₹29.02 crore in net profit.
Past quarterly results for Cohance Lifesciences Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.